<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8"/>
		<title>BCSC1819_S12_C08_p175-188</title>
		<link href="BCSC1819_S12_C08_p175-188-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1819_S12_C08_p175-188" lang="en-US">
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">CHAPTER</span><span class="cn-chap"> </span>8</p>
			<p class="chapter-title ParaOverride-1">Retinopathy of Prematurity</p>
			<p class="activity-intro ParaOverride-2"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" /> This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or going to <a href="http://www.aao.org/bcscvideo_section12">www.aao.org/bcscvideo_section12</a>.</p>
			<p class="h1 ParaOverride-3">Introduction</p>
			<div id="Chapt8_Top1">
			<p class="body-text--no-indent-">Retinopathy of prematurity (ROP) is a complex disease pro&#173;cess initiated in part by a lack of complete or normal ret&#173;i&#173;nal vascularization in premature infants. ROP has a typical progression pattern, but the earlier disease stages may regress spontaneously at any time. The absence of ret&#173;i&#173;nal vessels in portions of the immature ret&#173;ina can result in ret&#173;i&#173;nal is&#173;chemia, leading to the release of growth &#173;factors that promote vascular growth. The normal vascular-&#173;growth pro&#173;cess is disturbed, and vessels proliferate into the vitreous cavity at the border of the vascular and avascular ret&#173;ina. As the disease progresses, vitreous hemorrhage and tractional ret&#173;i&#173;nal detachment can occur. The end stage of untreated ROP is the development of a dense, white, fibrovascular plaque &#173;behind the lens and complete tractional ret&#173;i&#173;nal detachment. The former name of this condition, <span class="italic">retrolental fibroplasia,</span> describes the end stage of ROP. The main risk &#173;factors for developing this condition are prematurity and low birth weight. Also see BCSC Section&#160;6, <span class="italic">Pediatric Ophthalmology and Strabismus,</span> for additional discussion of ROP.</p>
			<p class="h2">Epidemiology</p>
			<p class="body-text--no-indent-">In the United States, ROP that is severe enough to require treatment occurs in approximately 1100–1500 infants annually. Among &#173;these infants, 400–600 &#173;will never achieve vision better than 20/200. In resource-&#173;limited regions of the world, &#173;there has been a rise in the incidence of ROP that corresponds to the establishment of neonatal intervention initiatives to treat premature infants who would not previously have survived. In many instances, &#173;there has been an unfortunate lag between successes in saving premature infants and successes in diagnosing and managing their subsequent ROP.</p>
			</div>
			<p class="h1">Terminology and Classification</p>
			<div id="Chapt8_Top2">
			<p class="body-text--no-indent-">An international classification of ROP was developed so that the disease could be consistently described, staged, and studied. Four classification concepts have prognostic and pathophysiologic importance: the location, or <span class="italic">zone,</span> of involvement; the disease severity, or <span class="italic">stage;</span> the <span class="italic">extent</span> of disease in clock-&#173;hours of involvement; and &#173;whether or not <span class="italic">plus disease</span> is pres&#173;ent. <span class="xref-table">&#173;Table&#160;8</span>-&#173;<span class="xref-table">1</span> goes into further detail about this impor&#173;tant terminology.</p>
			<p class="body-text">Based on this terminology, ROP can be classified into several disease stages and severities to aid clinicians in making management and treatment decisions (<span class="xref-table">&#173;Table&#160;8</span>-&#173;<span class="xref-table">2</span>). <span class="italic">Aggressive posterior ROP</span> (also referred to as <span class="italic">rush disease</span>) is characterized by the presence of vascularization that ends in zone I or very posterior zone II and is accompanied by plus disease. <span class="italic">Threshold disease</span> is characterized by more than 5 contiguous clock-&#173;hours of extraret&#173;i&#173;nal neovascularization or 8 cumulative clock-&#173;hours of extraret&#173;i&#173;nal neovascularization in association with plus disease and location of the ret&#173;i&#173;nal vessels within zone I or II (<span class="xref-figure">Fig 8</span>-&#173;<span class="xref-figure">7</span>). <span class="italic">Prethreshold disease</span> is a term created by the Early Treatment for Retinopathy of Prematurity (ETROP) study; it encompasses all zone I and zone II ROP changes that do not meet threshold treatment criteria, except for zone II stage 1 and zone&#160;II stage 2 without plus disease. Prethreshold disease can be further divided into high-&#173;risk prethreshold ROP, or <span class="italic">type 1 ROP,</span> and lower-&#173;risk prethreshold ROP, or <span class="italic">type 2 ROP</span> (see &#173;<span class="xref-table">Table&#160;8-2</span>).</p>
			<p class="body-text">An eye is classified according to the most advanced disease noted; however, documentation should reflect all zones and stages observed, including their relative extent. Eyes with ROP in zone III typically have a good visual prognosis. The more posterior the zone at the time of recognition of the disease, the more nonperfused ret&#173;ina &#173;there is and thus the more worrisome the prognosis.</p>
			<p class="reference--journal--single ParaOverride-4">International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. <span class="italic">Arch Ophthalmol.</span> 2005;123(7):<br />991–999.</p>
			</div>
			<p class="h1">Pathophysiology of ROP</p>
			<div id="Chapt8_Top3">
			<p class="body-text--no-indent-">Typically, ret&#173;i&#173;nal vascularization begins at approximately week 16 of gestation, proceeds from the optic nerve head to the periphery, and is completed nasally by approximately 36 weeks’ gestation and temporally by 40 weeks’ gestation. When this pattern of vascularization is disrupted, ROP may develop. Although the current understanding of the pathophysiology of ROP is incomplete, it is thought of as a 2-&#173;phase pro&#173;cess. In the first phase, which occurs before approximately 31 weeks’ gestational age, typical vascular development ceases. This cessation occurs largely as the result of a decrease in the levels of hormones and growth &#173;factors that govern normal vascular development in the eye, such as vascular endothelial growth &#173;factor (VEGF) and insulin-&#173;like growth &#173;factor 1 (IGF-1). The drop in the expression and levels of &#173;these growth &#173;factors is thought to be caused by an increase in the infant’s systemic oxygen tension that occurs following birth and the commencement of breathing by the infant.</p>
			<p class="body-text">The second phase of ROP begins at approximately 31–34 weeks’ gestational age. It is characterized by an abundance of growth &#173;factors secreted by the ischemic retina—&#173;particularly VEGF and IGF-1, among &#173;others—as well as by oxidative damage to endothelial cells, which leads to disor&#173;ga&#173;nized vascular growth. Initially, this pro&#173;cess &#173;causes the formation of a vis&#173;i&#173;ble tissue ridge (ROP stages 1, 2). As the disease progresses, vascular growth proliferates into the vitreous cavity (ROP stage 3). Eventually, growth &#173;factor and hormone shifts cause involution of the blood vessels with cicatricial contraction, which can lead to tractional ret&#173;i&#173;nal detachment (ROP stages 4, 5).</p>
			<p class="body-text">The more peripheral the neovascularization and the smaller its size and extent on the ret&#173;ina, the better the outlook is for spontaneous regression with minimal scarring. Active neovascularization with shunting of blood flow is associated with dilation and increased tortuosity of the ret&#173;i&#173;nal vessels posteriorly. A notable finding in active disease is the increased and abnormal terminal arborization of ret&#173;i&#173;nal vessels as they approach the shunt or ridge. In addition, microvascular abnormalities (eg, microaneurysms, areas of capillary nonperfusion, and dilated vessels) may be vis&#173;i&#173;ble posterior to the ridge.</p>
			<p class="body-text">In the vasoproliferative phase, new vessels varying widely in size and extent arise from ret&#173;i&#173;nal vessels just posterior to the shunt. &#173;These new vessels can induce contracture of the firmly attached vitreous gel, which results in progressive tractional ret&#173;i&#173;nal detachment. Vitreous hemorrhage can occur in stages 3–5, as can exudative ret&#173;i&#173;nal detachment.</p>
			<p class="reference--journal--single">Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. <span class="italic">N Engl J&#160;Med.</span> 2012;367(26):2515–2526.</p>
			<p class="h2 ParaOverride-5">Natu&#173;ral Course</p>
			<p class="body-text--no-indent-">Although the systemic and/or local tissue &#173;factors that influence progression and regression of ROP are not known, the time course is predictable. ROP is a transient disease in the majority of infants, and spontaneous regression occurs in 85% of eyes. The initial clinical sign of regression is the development of a clear zone of ret&#173;ina beyond the shunt, followed by the development of straight vessels crossing the shunt and an arteriovenous feeder extending into the avascular ret&#173;i&#173;na.</p>
			<p class="body-text">Threshold ROP eventually develops in approximately 7%–10% of infants with a birth weight of 1250&#160;g or less. Eyes that demonstrate progression undergo a gradual transition from the active to the cicatricial stage of ROP, which is associated with variable degrees of fibrosis, contracture of the proliferative tissue, vitreous and ret&#173;i&#173;nal traction, macular distortion, vitreous and ret&#173;i&#173;nal hemorrhages, and/or ret&#173;i&#173;nal detachment.</p>
			<p class="h2 ParaOverride-5">Associated Conditions and Late Sequelae</p>
			<p class="body-text--no-indent-">Conditions more likely to occur in eyes with regressed ROP include the following:</p>
			<ul>
				<li class="bullet-list-first">myopia with astigmatism</li>
				<li class="bullet-list-mid">anisometropia</li>
				<li class="bullet-list-mid">strabismus</li>
				<li class="bullet-list-mid">amblyopia</li>
				<li class="bullet-list-mid">cataract</li>
				<li class="bullet-list-mid">glaucoma</li>
				<li class="bullet-list-mid">macular pigment epitheliopathy</li>
				<li class="bullet-list-mid">vitreoret&#173;i&#173;nal scarring</li>
				<li class="bullet-list-mid">abnormal vitreoret&#173;i&#173;nal interface/adhesions</li>
				<li class="bullet-list-mid">tractional ret&#173;i&#173;nal detachment</li>
				<li class="bullet-list-last">anomalous foveal anatomy</li>
			</ul>
			<p class="body-text">Though rare, both angle-&#173;closure and pupillary-&#173;block glaucoma may occur in myopic eyes with cicatricial ROP. Angle-&#173;closure glaucoma typically occurs before 10&#160;years of age, but it can occur well into adulthood in affected individuals. Rhegmatogenous ret&#173;i&#173;nal detachment, exudative retinopathy, and recurrent vitreous hemorrhages can also occur &#173;later in life. ROP and its sequelae can cause prob&#173;lems throughout a patient’s life; therefore, long-&#173;term monitoring is crucial.</p>
			<p class="body-text">Unfortunately, even with the current guidelines for screening and treatment, approximately 400–600 infants become legally blind from ROP each year in the United States. Poor outcomes from ROP may be perceived as medical malpractice and therefore pose a risk for litigation by patients or their families. The Ophthalmic Mutual Insurance Com&#173;pany (<a href="http://www.OMIC.com">www.OMIC.com</a>) offers numerous tools to assist ophthalmologists in limiting their liability risk.</p>
			<p class="reference--journal--single">Day S, Menke AM, Abbott RL. Retinopathy of prematurity malpractice claims: the Ophthalmic Mutual Insurance Com&#173;pany experience. <span class="italic">Arch Ophthalmol.</span> 2009;127(6):794–798.</p>
			</div>
			<p class="h1 ParaOverride-6">Screening Recommendations</p>
			<div id="Chapt8_Top4">
			<p class="body-text--no-indent-">The Cryotherapy for Retinopathy of Prematurity Cooperative Group determined that signs of ROP &#173;were pres&#173;ent in 66% of infants with a birth weight of 1250&#160;g or less and in 82% of infants with a birth weight of less than 1000&#160;g. Recommendations for the screening examination of premature infants at risk for ROP have been issued in a joint statement of the American Acad&#173;emy of Pediatrics, Section on Ophthalmology; the American Association for Pediatric Ophthalmology and Strabismus; and the American Acad&#173;emy&#160;of Ophthalmology (available at <a href="http://www.aao.org/clinical-statement/screening-examination-of-premature-infants-retinop">www.aao.org/clinical-statement/screening-examination<br />-of-premature-infants-retinop</a>). Screening should consist of a dilated fundus examination using binocular indirect ophthalmoscopy. Alternatively, &#173;there are telemedicine (photographic) screening approaches that can substitute for the indirect ophthalmoscopic examination (see the section Fundus Photographic Screening of ROP).</p>
			<p class="body-text">One caveat of paramount importance to recognize is that screening criteria and risk &#173;factors developed in one country do not necessarily apply in another country, especially if the level or quality of available medical or perinatal care is not comparable. For example, in some countries ROP is seen in babies with a higher birth weight than in the United States; thus, screening criteria need to be developed that reflect local experiences.</p>
			<p class="h2">Screening Criteria</p>
			<p class="body-text--no-indent-">All infants with a birth weight of less than 1500&#160;g or a gestational age of 30 weeks or less should be screened. In addition, infants with a birth weight between 1500&#160;g and 2000&#160;g or a gestational age greater than 30 weeks, with an unstable clinical course, and who are believed to be at high risk by their attending pediatricians or neonatologists should be screened. The first examination should generally be performed between 4 and 6 weeks of postnatal age or, alternatively, between 31 and 33 weeks’ postconceptional or postmenstrual age, whichever is &#173;later.</p>
			<p class="body-text">Systemic IGF-1 levels and weight gain are also associated with ROP risk. Taken together, the rate of weight gain and IGF-1 levels are more predictive of ROP development than is &#173;either value alone. A newer model—&#173;the weight, IGF-1, neonatal ROP (WINROP) algorithm—is being assessed for more targeted screening efforts, replacing the conventional screening criteria. In some studies, this model has been 100% sensitive in detecting at-&#173;risk infants while identifying as many as 90% of infants that do not need screening. The WINROP model has led to interest in developing other, preferably simpler, algorithms to identify infants at risk for ROP who &#173;will require screening.</p>
			<p class="h2">Screening Intervals</p>
			<p class="body-text--no-indent-">&#173;After each evaluation, the follow-up interval should be determined based on the disease features; more severe disease indicates a need for shorter follow-up intervals.</p>
			<p class="bullet-list-head ParaOverride-7">1-&#173;Week or Less Follow-&#173;up</p>
			<ul>
				<li class="bullet-list-first ParaOverride-8">immature vascularization: zone I—no ROP</li>
				<li class="bullet-list-mid">immature ret&#173;ina extends into posterior zone II, near the boundary of zone I</li>
				<li class="bullet-list-mid">stage 1 or 2 ROP: zone I</li>
				<li class="bullet-list-mid">stage 3 ROP: zone II</li>
				<li class="bullet-list-last ParaOverride-9">the presence or suspected presence of aggressive posterior ROP</li>
			</ul>
			<p class="bullet-list-head ParaOverride-7">1-&#173; to 2-&#173;Week Follow-&#173;up</p>
			<ul>
				<li class="bullet-list-first ParaOverride-8">immature vascularization; posterior zone II</li>
				<li class="bullet-list-mid">stage 2 ROP: zone II</li>
				<li class="bullet-list-last ParaOverride-9">unequivocally regressing ROP: zone I</li>
			</ul>
			<p class="bullet-list-head ParaOverride-7">2-&#173;Week Follow-&#173;up</p>
			<ul>
				<li class="bullet-list-first ParaOverride-8">stage 1 ROP: zone II</li>
				<li class="bullet-list-mid">immature vascularization: zone II—no ROP</li>
				<li class="bullet-list-last ParaOverride-9">unequivocally regressing ROP: zone II</li>
			</ul>
			<p class="bullet-list-head ParaOverride-7">2-&#173; to 3-&#173;Week Follow-&#173;up</p>
			<ul>
				<li class="bullet-list-first ParaOverride-8">stage 1 or 2 ROP: zone III</li>
				<li class="bullet-list-last">regressing ROP: zone III</li>
			</ul>
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal screening examinations can usually be discontinued when any one of the following criteria is met:</p>
			<ul>
				<li class="bullet-list-first">zone III ret&#173;i&#173;nal vascularization attained without previous zone I or II ROP (if &#173;there is examiner doubt about the zone or if the postmenstrual age is less than 35 weeks, confirmatory examinations may be warranted);</li>
				<li class="bullet-list-mid">full ret&#173;i&#173;nal vascularization in close proximity to the ora serrata for 360°—&#173;that is, the normal distance found in mature ret&#173;ina between the end of vascularization and the ora serrata. This criterion should be used for all cases treated for ROP solely with bevacizumab;</li>
				<li class="bullet-list-mid">postmenstrual age of 50 weeks and no prethreshold disease or more severe ROP is pres&#173;ent; or</li>
				<li class="bullet-list-mid">regression of ROP (care must be taken to ensure that &#173;there is no abnormal vascular tissue pres&#173;ent that is capable of reactivation and progression in zone II or III).<p class="reference--journal--single ParaOverride-10">Fierson WM; American Acad&#173;emy of Pediatrics Section on Ophthalmology; American Acad&#173;emy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. <span class="italic">Pediatrics.</span> 2013;131(1):189–195.</p></li>
			</ul>
			<p class="h2">Fundus Photographic Screening of ROP</p>
			<p class="body-text--no-indent-">Ultra-&#173;wide-&#173;angle (120°) fundus photography of premature infant eyes is very useful for documenting the findings, for assessing any progression, and for use in fundus photographic screening. Remote screening of photographic fundus images has established itself as an efficient and cost-&#173;effective method for screening premature infants for ROP. A study by the Photographic Screening for Retinopathy of Prematurity (Photo-&#173;ROP) Cooperative Group concluded that remote interpretation of weekly digital fundus images was a useful adjunct to conventional bedside ROP screening by indirect ophthalmoscopy. The study also concluded that &#173;because of limitations of image quality in some cases, &#173;there continues to be a need for the availability of an ophthalmologist skilled at examining premature infant eyes. In addition, the study established that if clinically significant ROP or treatment requiring ROP (&#173;<span class="xref-table">Table&#160;8-3</span>) is pres&#173;ent, an evaluation by an ophthalmologist for assessment and pos&#173;si&#173;ble treatment is warranted.</p>
			</div>
			<p class="h1 ParaOverride-6">Prevention and Risk Factors</p>
			<div id="Chapt8_Top5">
			<p class="body-text--no-indent-">As ROP became a clinically distinct and recognized entity in the 1950s, supplemental oxygen administration was implicated as a major causative &#173;factor. &#173;After substantial reductions in oxygen use in neonatal intensive care units, the incidence of ROP decreased dramatically. However, many of the infants incurred adverse neurologic outcomes as an unintended consequence of that oxygen restriction, and infant death rates &#173;rose. Once oxygen was again used more liberally, neurologic outcomes and survival improved, with the consequence of a resurgence of ROP.</p>
			<p class="body-text">Preventing ROP begins with preventing prematurity through optimal prenatal, perinatal, and postnatal care. Avoiding extremely low birth weight and short gestational ages may be the most impor&#173;tant &#173;factors in prevention. &#173;There is mounting evidence that the postnatal clinical course alters risk as well; that is, very sick premature infants are at greater risk of developing ROP. Specific &#173;factors shown to increase the risk of ROP are sepsis, blood transfusion, and a slow rate of postnatal weight gain.</p>
			<p class="body-text">Diet has been recognized as an additional risk &#173;factor. Several studies are currently &#173;under way to assess nutritional interventions for reducing the risk of ROP; one such intervention is addition of the sugar inositol to the neonate’s diet (formula) or parenteral nutrition.</p>
			<p class="reference--journal--single ParaOverride-7">BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-&#173;Mordi WO, Darlow BA, et&#160;al. Oxygen saturation and outcomes in preterm infants. <span class="italic">N Engl J Med.</span> 2013;368(22):<br />2094–2104.</p>
			</div>
			<p class="h1 ParaOverride-6">Treatment</p>
			<div id="Chapt8_Top6">
			<p class="body-text--no-indent-">In 1988, the Cryotherapy for ROP study demonstrated that ablation of the avascular anterior ret&#173;ina in ROP eyes with threshold disease reduced by approximately half the incidence of unfavorable outcomes (eg, macular dragging, ret&#173;i&#173;nal detachment, and retrolental cicatrix formation). Treatment reduced &#173;these sequelae from 47% to 25% at 1 year follow-up, and visual results &#173;were shown to parallel anatomical results. At 10&#160;years, eyes that received cryotherapy &#173;were still much less likely to be blind than untreated control eyes.</p>
			<p class="body-text">The ETROP trial randomly assigned 1 eye of infants with bilateral, high-&#173;risk, prethreshold ROP to receive early ablation of the avascular ret&#173;ina and the fellow eye to receive conventional management according to Cryotherapy for ROP study methods. High risk was determined using a computational model based on the natu&#173;ral history cohort of the Cryotherapy for ROP study; this model used demographic characteristics of the infants and clinical features of ROP to classify eyes with prethreshold ROP as &#173;either high risk or low risk. In infants with high-&#173;risk prethreshold ROP, earlier treatment was associated with a reduction in unfavorable visual acuity outcomes (from 19.5% to 14.5%; <span class="italic">P</span> <span class="symbol">=</span> .01) and a reduction in unfavorable structural outcomes (from 15.6% to 9.1%; <span class="italic">P</span> <span class="symbol">&lt;</span> .001) at 9&#160;months. The study determined that the clinical categorization of prethreshold eyes into type 1 or type 2 ROP achieved very similar results to the computational model for risk assessment to prethreshold eyes.</p>
			<p class="body-text">Any eyes meeting the criteria for type 1 ROP should be considered for peripheral ret&#173;i&#173;nal ablative treatment, whereas type 2 ROP eyes can be monitored in short intervals; &#173;laser ablative treatment can be considered if type 2 ROP eyes pro&#173;gress to type 1 ROP or threshold ROP. The authors of the ETROP study pointed out that the prethreshold treatment algorithm did not account for all other known risk &#173;factors for ROP progression, such as systemic disease, and that clinical judgment is still required for optimal disease management.</p>
			<p class="reference--journal--first ParaOverride-7">Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. <span class="italic">Arch Ophthalmol.</span> 2003;121(12):1684–1694.</p>
			<p class="reference--non-journal--mid">Shulman JP, Hobbs R, Hartnett ME. Retinopathy of prematurity: evolving concepts in diagnosis and management. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2015, module 1.</p>
			<p class="h2 ParaOverride-11">&#173;Laser and Cryoablation Surgery</p>
			<p class="body-text--no-indent-">Ablation treatment of threshold or prethreshold type 1 ROP should be performed with &#173;laser surgery rather than cryoablation surgery whenever pos&#173;si&#173;ble, &#173;because &#173;laser surgery is associated with less treatment-&#173;related morbidity. Treatment should be administered within 72 hours of determining its need and applied using the indirect ophthalmoscope in a confluent or subconfluent scatter pattern to the avascular ret&#173;ina anterior to the ridge (<span class="xref-figure">Fig 8</span>-&#173;<span class="xref-figure">8</span>). In the horizontal meridians, &#173;laser treatment should be applied in a lighter pattern to avoid damage to the long ciliary vessels and nerves; damage to &#173;these structures can lead to severe anterior segment ischemia. Although the use of ret&#173;i&#173;nal cryoablation surgery is now rare (in the United States), the technique may still have a role in the treatment of eyes with media opacities or per&#173;sis&#173;tent tunica vasculosa lentis, or when a &#173;laser is not available. &#173;Because respiratory or cardiorespiratory arrest can occur in up to 5% of treated infants, treatment should be performed in conjunction with pediatric consultation and with systemic monitoring. Use of systemic analgesia is also advisable to minimize stress and risk to the infant. Some neonatologists prefer that infants undergo treatment with general anesthesia in an operating room.</p>
			<p class="reference--journal--first">Brown GC, Tasman WS, Naidoff M, Schaffer DB, Quinn G, Bhutani VK. Systemic complications associated with ret&#173;i&#173;nal cryoablation for retinopathy of prematurity. <span class="italic">Ophthalmology.</span> 1990;97(7):855–858.</p>
			<p class="reference--journal--mid">Connolly BP, McNamara JA, Sharma S, Regillo CD, Tasman&#160;W. A comparison of &#173;laser photo&#173;coagulation with trans-&#173;scleral cryotherapy in the treatment of threshold retinopathy of prematurity. <span class="italic">Ophthalmology.</span> 1998;105(9):1628–1631.</p>
			<p class="reference--journal--last ParaOverride-12">&#173;Laser ROP Study Group. &#173;Laser therapy for retinopathy of prematurity. <span class="italic">Arch Ophthalmol.</span> 1994;<br />112(2):154–156.</p>
			<p class="h2">Anti-&#173;VEGF Drugs</p>
			<p class="body-text--no-indent-">The BEAT-&#173;ROP (Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity) Cooperative Group conducted a prospective, randomized, multicenter trial to assess intravitreal bevacizumab monotherapy for zone I or zone II posterior stage 3 ROP with plus disease. Compared with conventional &#173;laser therapy, a statistically significant treatment benefit for bevacizumab was demonstrated for zone I ROP, whereas zone II disease had similar outcomes with &#173;either treatment. Normal peripheral ret&#173;i&#173;nal vascularization continued &#173;after treatment with intravitreal bevacizumab, whereas &#173;laser therapy led to permanent destruction of the peripheral ret&#173;ina. Recurrences occurred significantly &#173;later with bevacizumab than with &#173;laser therapy. Therefore, prolonged, close follow-up is essential. The study was too small and the follow-up period too short to allow proper evaluation of the safety of intravitreal bevacizumab for the treatment of ROP. Infants treated with anti-&#173;VEGF monotherapy have an incidence of recurrence of 8.3% and a mean recurrence time of 51.2 weeks. If available, fluorescein angiography is a &#173;great tool for follow-up of treated patients to assess eyes for reactivation or progression of the retinopathy.</p>
			<p class="body-text">The results of the BEAT-&#173;ROP study, and other published evidence, have dramatically changed how zone I ROP, and prob&#173;ably all ROP, is treated. However, to date &#173;little data are available that assess the safety, especially the long-&#173;term safety, of using anti-&#173;VEGF therapy to treat ROP. Furthermore, &#173;there is mounting evidence that the disease can recur or reactivate following anti-&#173;VEGF treatment, which is rarely seen following ablative therapy. Continued investigation of long-&#173;term safety and efficacy data remains critical for understanding the exact role of anti-&#173;VEGF therapy in the management of this unique population.</p>
			<p class="reference--journal--first">Mintz-&#173;Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity &#173;after intravitreal bevacizumab monotherapy. <span class="italic">Ophthalmology.</span> 2016;<br />123(9):1845–1855.</p>
			<p class="reference--journal--last ParaOverride-12">Mintz-&#173;Hittner HA, Kennedy KA, Chuang AZ; BEAT-&#173;ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. <span class="italic">N Engl J Med.</span> 2011;<br />364(7):603–615.</p>
			<p class="h3">Intravitreal injection technique</p>
			<p class="body-text--no-indent-">Intravitreal injections can be performed at the patient’s bedside in the neonatal intensive care unit (NICU) (Video 8-1). The preparation is very similar to that of an adult intravitreal injection. The neonatal nurse prepares the infant for the injection. The eye is sterilized with a 5% betadine solution. A sterile eyelid speculum for each eye is used to retract the lids. Given an infant’s small eye size, the injection site should be 1.5&#160;mm posterior to the limbus, compared with 3–4&#160;mm in adults. Meticulous attention must be paid to the lens anatomy to avoid puncturing it with the injection needle, &#173;because the lens is larger in premature infants relative to the overall eye size compared with adults. Risks associated with the injection include cataracts, endophthalmitis, bleeding, and retinal detachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-13"> <span class="QR-code-number">VIDEO 8-1</span> Intravitreal injection at bedside.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source ParaOverride-13">Courtesy of Audina&#160;M. Berrocal, MD.</p>
			<p class="QR-code-text-last ParaOverride-14">Access all Section 12 videos at <a href="http://www.aao.org/bcscvideo_section12"><span class="Hyperlink">www.aao.org</span><span class="Hyperlink">/</span><span class="Hyperlink">bcscvideo_section12</span></a>.</p>
			<p class="h2">Vitrectomy and Scleral Buckling Surgery</p>
			<p class="body-text--no-indent-">Eyes with stage 4 ROP (progressive, active-&#173;phase ROP) require surgical intervention using scleral buckling or a lens-&#173;sparing vitrectomy to alleviate the vitreoret&#173;i&#173;nal traction causing ret&#173;i&#173;nal detachment. Eyes undergoing surgical intervention at stage 4A—&#173;rather than at &#173;later stages 4B or 5—&#173;have more favorable outcomes. Lens-&#173;sparing vitrectomy for stage&#160;4A ROP may reduce the progression to stages 4B and 5 ROP; given the improved visual outcome, this is the preferred approach. New microincisional instrumentation is available to facilitate surgery in the smaller-&#173;sized infant eyes.</p>
			<p class="body-text">For eyes with stage 5 disease, vitrectomy combined with dissection of the fibrovascular membranes and adherent vitreous has been successful in fully or partially reattaching the ret&#173;ina in approximately 30% of eyes (Video 8-2). Nevertheless, only 25% of ret&#173;i&#173;nas in eyes with initial partial or total reattachment &#173;after surgery remained fully attached a median of 5&#160;years &#173;later. Among the patients whose ret&#173;i&#173;nas &#173;were initially reattached, only 10% eventually have ambulatory vision. If a drainage retinotomy is performed or an iatrogenic ret&#173;i&#173;nal break occurs during a vitrectomy for ROP, the prognosis for that eye becomes uniformly poor.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-15"> <span class="QR-code-number">VIDEO 8-2</span> Stage 5 ROP surgery.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto ParaOverride-15">Courtesy of Audina&#160;M. Berrocal, MD.</p>
			<p class="reference--journal--first ParaOverride-16">Capone A Jr, Trese MT. Lens-&#173;sparing vitreous surgery for tractional stage 4A retinopathy of prematurity ret&#173;i&#173;nal detachments. <span class="italic">Ophthalmology.</span> 2001;108(11):2068–2070.</p>
			<p class="reference--journal--last">Quinn GE, Dobson V, Barr CC, et&#160;al. Visual acuity of eyes &#173;after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2&#160;years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. <span class="italic">Ophthalmology.</span> 1996;103(4):595–600.</p>
		</div>
		</div>
		<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
			<table id="table001" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title- CellOverride-1" colspan="2">
							<p class="table-title"><span class="table-number">Table&#160;8-1</span> Descriptive Terminology for Acute Retinopathy of Prematurity</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-2 _idGenCellOverride-1" colspan="2">
							<p class="table-body"><span class="table-italic-bold">Location</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Zone I:</span> posterior ret&#173;ina within a 60° circle centered on the optic nerve</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Zone II:</span> from the posterior circle (zone I) to the nasal ora serrata anteriorly</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Zone III:</span> remaining temporal peripheral ret&#173;ina</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-4" colspan="2">
							<p class="table-body"><span class="table-italic-bold">Extent:</span> number of clock-&#173;hours involved</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="table-italic-bold">Severity</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 0:</span> immature ret&#173;i&#173;nal vasculature without pathologic changes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 1:</span> presence of a demarcation line between vascularized and nonvascularized ret&#173;ina (<span class="xref-figure">Fig 8-1</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 2:</span> presence of a demarcation line that has height, width, and volume (ridge); small, isolated tufts of neovascular tissue lying on the surface of the ret&#173;ina, commonly called “popcorn,” may be pres&#173;ent (<span class="xref-figure">Fig 8-2</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 3:</span> a ridge with extraret&#173;i&#173;nal fibrovascular proliferation that may be mild, moderate, or severe, as judged by the amount of proliferative tissue pres&#173;ent (<span class="xref-figure">Fig 8-3</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 4:</span> partial ret&#173;i&#173;nal detachment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body ParaOverride-17">A. extrafoveal</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body ParaOverride-17">B. ret&#173;i&#173;nal detachment including fovea (<span class="xref-figure">Fig 8-4</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-3" colspan="2">
							<p class="table-body"><span class="bold-table">Stage 5:</span> total ret&#173;i&#173;nal detachment with funnel configuration; combinations are listed in order of frequency: top row is the most common configuration and bottom row the least common configuration (<span class="xref-figure">Fig 8-5</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-17"><span class="table-italic">Anterior</span></p>
							<p class="table-body ParaOverride-17">Open</p>
							<p class="table-body ParaOverride-17">Narrow</p>
							<p class="table-body ParaOverride-17">Open</p>
							<p class="table-body ParaOverride-17">Narrow</p>
						</td>
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-18"><span class="table-italic">Posterior</span></p>
							<p class="table-body ParaOverride-18">Open</p>
							<p class="table-body ParaOverride-18">Narrow</p>
							<p class="table-body ParaOverride-18">Narrow</p>
							<p class="table-body ParaOverride-18">Open</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-6 _idGenCellOverride-2" colspan="2">
							<p class="table-body"><span class="table-italic-bold">Plus disease:</span> vascular dilatation (venous) and tortuosity (arteriolar) of posterior ret&#173;i&#173;nal vessels in&#160;at least 2 quadrants of the eye; iris vascular dilatation and vitreous haze may be pres&#173;ent (<span class="xref-figure">Fig&#160;8-6</span>)</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-7591.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 8-1</span> Stage 1 retinopathy of prematurity (ROP). Fundus photograph reveals a faint demarcation line present temporally. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-7592.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer012" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 8-2</span> Stage 2 ROP. Fundus photograph shows an elevated ridge of mesenchymal tissue at the border of the vascularized (reddish) and avascular (grayish) retina. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer015">
				<div id="_idContainer013" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-7593.jpg" alt="" />
				</div>
				<div id="_idContainer014" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-3</span> Stage 3 ROP. Fundus photograph shows an eye with severe stage 3 ROP with marked preretinal proliferations. Some vitreous and preretinal hemorrhage is visible <span class="figure-caption-italic">(lower right)</span>. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer018">
				<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/KIN00932.png" alt="" />
				</div>
				<div id="_idContainer017" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-4</span> Stage 4 ROP. <span class="figure-caption-bold">A,</span> Schematic representation shows stage 4A ROP. <span class="figure-caption-bold">B,</span> In this representation of stage 4B ROP, the roman numerals in each circle indicate the zones, as per the international classification, and the arabic numerals indicate clock-hours. <span class="figure-caption-bold">C,</span> Wide-angle clinical&#160;photograph shows a stage 4A retinal detachment in an eye with ROP. <span class="figure-caption-bold">D,</span> Wide-angle clinical photograph shows a stage 4B retinal detachment. <span class="figure-source-note">(Parts A, B courtesy of J. Arch McNamara, MD; parts C, </span><span class="figure-source-note">D courtesy of Audina Berrocal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer021">
				<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-9880.png" alt="" />
				</div>
				<div id="_idContainer020" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-5</span> Stage 5 ROP. Each of the wide-angle fundus photographs shows examples of total ROP retinal detachment <span class="figure-caption-bold">(A–C).</span> The marked contraction of the preretinal fibrosis acts like a purse string. Even at this stage—an open-funnel stage 5 retinal detachment—the arborizing pattern of the retinal blood vessels approaching the preretinal proliferation is visible. Additionally, tortuous dilated vessels, also called plus disease, are present in each image. <span class="figure-source-note">(Part A courtesy of Colin A. McCannel, MD; parts B, C courtesy of Audina Berrocal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
			<table id="table002" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-10" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title- CellOverride-1">
							<p class="table-title"><span class="table-number">Table&#160;8-2</span> Classification of Acute Retinopathy of Prematurity (ROP)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-2 _idGenCellOverride-1">
							<p class="table-body"><span class="bold-table">Aggressive posterior ROP (also referred to as rush disease)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-19">Vascularization ends in zone I or very posterior zone II and is accompanied by plus disease; may pro&#173;gress rapidly</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-7">
							<p class="table-body"><span class="bold-table">Threshold disease</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-19">5 contiguous clock-&#173;hours of extraret&#173;i&#173;nal neovascularization</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-19">or</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-19">8 cumulative clock-&#173;hours of extraret&#173;i&#173;nal neovascularization in association with plus disease and location of the ret&#173;i&#173;nal vessels within zone I or II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-7">
							<p class="table-body"><span class="bold-table">Prethreshold disease</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-19">All zone I and zone II changes, except zone II stage 1, and zone II stage 2 without plus disease, that do not meet threshold treatment criteria, and subdivided into type 1 and type 2 disease:</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-20"><span class="table-italic">Type 1</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-21">zone I, any stage ROP with plus disease, or</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-21">zone I, stage 3 ROP without plus disease, or</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-21">zone II, stage 2 or 3 ROP with plus disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-20"><span class="table-italic">Type 2</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body ParaOverride-21">zone I, stage 1 or 2 ROP without plus disease, or</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-6 _idGenCellOverride-2">
							<p class="table-body ParaOverride-21">zone II, stage 3 ROP without plus disease</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer025">
				<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-9883.png" alt="" />
				</div>
				<div id="_idContainer024" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-6</span> Fundus photographs show pronounced plus disease in eyes with ROP. The retinal arteries and veins are dilated and tortuous. <span class="figure-caption-bold">A,</span> The avascular retina and preretinal proliferations can be seen inferiorly and inferotemporally <span class="figure-caption-italic">(bottom right)</span>. <span class="figure-caption-bold">B,</span> Photograph shows an eye with plus disease without notable preretinal fibrosis. <span class="figure-caption-bold">C,</span> Preretinal hemorrhage is visible, originating from the proliferative disease. <span class="figure-source-note">(Part A courtesy of Colin A. McCannel, MD; parts B, C courtesy of Audina Berrocal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028">
				<div id="_idContainer026" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-8211.png" alt="" />
				</div>
				<div id="_idContainer027" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-7</span> Illustrations of threshold disease, as characterized in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. <span class="figure-caption-italic">Right,</span> 8 cumulative, noncontiguous clock-hours of stage 3 disease. <span class="figure-caption-italic">Left,</span> 5 contiguous clock-hours of proliferation. <span class="figure-source-note">(Illustration by Mark M. Miller.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
			<table id="table003" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-13" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table _1-BCSC-table-title- CellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table&#160;8-3</span> Definitions of Clinically Significant Retinopathy of Prematurity (CSROP) and ROP Requiring Treatment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-2 _idGenCellOverride-1" />
						<td class="Basic-Table CellOverride-2 _idGenCellOverride-1">
							<p class="table-body"><span class="bold-table">CSROP</span></p>
						</td>
						<td class="Basic-Table CellOverride-2 _idGenCellOverride-1" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"> (i) zone I, any ROP without plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"> (ii) zone II, stage 2 with no plus disease or up to 1 quadrant of plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"> (iii) zone II, stage 3 with no plus disease or up to 1 quadrant of plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-7" />
						<td class="Basic-Table CellOverride-7">
							<p class="table-body"><span class="bold-table">ROP requiring treatment (according to ETROP criteria)</span></p>
						</td>
						<td class="Basic-Table CellOverride-7" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"> (i) zone I, any ROP with plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"> (ii) zone I, stage 3 ROP without plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-6 _idGenCellOverride-2" />
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-6 _idGenCellOverride-2">
							<p class="table-body"> (iii) zone II, stages 2 or 3 ROP, with 2 or more quadrants of plus disease</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-6 _idGenCellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-8 _idGenCellOverride-3" colspan="3">
							<p class="table-source-note">Modified with permission from Photographic Screening for Retinopathy of Prematurity (Photo-&#173;ROP) &#173;Cooperative Group; Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese MT.  The Photographic Screening for Retinopathy of Prematurity Study (Photo-&#173;ROP): study design and baseline characteristics of enrolled patients. <span class="table-source-italic">Ret&#173;i&#173;na.</span> 2006;26(7 Suppl):S4–10.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032">
				<div id="_idContainer030" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C08_p175-188-web-resources/image/AAX-9886.png" alt="" />
				</div>
				<div id="_idContainer031" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-8</span> Wide-angle photograph shows a fundus after it has undergone laser photocoagulation for threshold ROP. <span class="figure-caption-bold">A,</span> Plus disease is visible posteriorly, and avascular retina is apparent in the inferior and inferior temporal fundus <span class="figure-caption-italic">(bottom right)</span>. Arborization of the vasculature leading up to the ridge and associated fibrovascular proliferation is pronounced. <span class="figure-caption-bold">B,</span> In a different patient, the image shows the pigment clumping, denoting healed laser photocoagulation, and the normalization of the retinal vasculature posteriorly. <span class="figure-source-note">(Part A courtesy of Colin A. McCannel, MD; part B courtesy of Audina Berrocal, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
